Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P
Service de Neurologie, Centre R. Garcin, Hôpital Sainte-Anne, Paris, France.
Neurology. 1993 Sep;43(9):1715-8. doi: 10.1212/wnl.43.9.1715.
We measured serum antibodies to botulinum toxin (ABT) in 96 patients with focal dystonia who had been treated with type A botulinum toxin. The frequency of detectable ABT was 3% (three patients). Patients with ABT had received more than 50 ng of botulinum toxin, and the shortest time between two injections was significantly less than in patients without ABT. The clinical evolution of the three patients was heterogeneous: one had decreased effectiveness with repeated injections, another had persistent improvement, and the third never responded to toxin injections.
我们检测了96例接受A型肉毒杆菌毒素治疗的局限性肌张力障碍患者的血清肉毒杆菌毒素抗体（ABT）。可检测到ABT的频率为3%（3例患者）。有ABT的患者接受的肉毒杆菌毒素超过50纳克，且两次注射之间的最短时间明显短于无ABT的患者。这3例患者的临床进展各不相同：1例重复注射后疗效降低，另1例持续改善，第3例对毒素注射无反应。
